Araclon Biotech S.l.

This Phase 2 study tested ABvac40, a vaccine designed to help the immune system target and clear a protein called amyloid-beta 40, which builds up in the brains of people with Alzheimer's. The trial included 134 adults aged 55-80 with mild cognitive impairment or very mild Alzhei…